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Introduction: Radiotherapy in combination with medical castration is the standard treatment for high-
risk prostate cancer. Some relapses may be explained by the presence of radioresistant clones arising
from hypoxic microenvironment. Since microRNAs (miR) are increased upon hypoxia, the aim of this
study was to see whether miR-210 is a potential marker for hypoxia and/or a therapeutic target in pros-
tate cancer.
Methods: Human LNCaP, DU145 or PC3 prostate cancer cells were exposed to normoxia or hypoxia for
several hours. Gene expression of miR-210, miR-373 and several hypoxia markers were analyzed by Taq-
man and SYBR green qRT-PCR, respectively. Clonogenic survival after LNA miR-210 inhibitor (78 nM) and
concomitant irradiation were evaluated.
Results: During anoxia, CAIX and VEGF expressions were dramatically increased. miR-210 expression
increased during anoxia exposure, while basal miR-373 expression was low and remained stable upon
anoxia. LNA miR-210 inhibitor decreased anoxic miR-210 expression by 90% and clonogenic survival
under anoxia (p = 0.01). However, no enhanced effect was observed when miR-210 inhibitor was com-
bined with irradiation.
Conclusion: miR-210 could be an interesting marker of chronic hypoxia irrespective of the androgen
dependency and should, therefore, be tested as a prognostic marker in high risk prostate cancer patients.
 2011 Elsevier Ireland Ltd. Open access under the Elsevier OA license.
Radiotherapy and Oncology 101 (2011) 203–208In Europe, prostate cancer is the leading cause of cancer inci-
dence and mortality in men with nearly 346,000 and 87,400 cases,
respectively, in 2006 [1]. Radiotherapy with or without medical
castration using LHRH (luteinizing hormone releasing hormone)
agonists is one of the standard treatments of localized prostate
cancer. Unfortunately, as much as 21% of patients may relapse clin-
ically after treatment [2]. Treatment failure depends on several
parameters such as number of clonogenic cells, the tumor growth
rate, the cell repair capacity, the intrinsic cellular radiosensitivity
and the tumor microenvironment. Tumor hypoxia or hypoxia
response could also be an explanation for treatment failure after
radiotherapy. Indeed, hypoxia is associated with poor disease-free
survival after radiotherapy in many cancers, such as head and neck
[3] and cervical cancers [4]. In localized prostate cancer, tumor
hypoxia is associated with poor prognosis, since low pO2 levels,
measured by Eppendorf microelectrode in prostate, was associated
with higher biochemical failure assessed by serum PSA (prostate
specific antigen) concentrations [5]. Furthermore, a significant cor-
relation was found between pre-operative prostate hypoxia leveldiation Oncology, Saint Louis
aris, France.
o).
nder the Elsevier OA license.measured by eppendorf oxygen microelectrodes and percentage
of cells staining positive for VEGF [6]. In an ancillary study from
the randomized trial GETUG-06 (French Genital and Urinary
Tumors Study Group), high expression of hypoxia markers HIF-
2a and CAIX, has been associated with poor biochemical control
after radiotherapy [7].
Two types of tumor hypoxia are recognized. Chronic hypoxia
results from the limited diffusion distance of oxygen in tissue,
whereas acute or transient hypoxia is caused by local fluctuations
in tumor blood perfusion [8]. Acute/cycling hypoxia has been
described as a major source of therapy resistance [9–11].
MicroRNA (miR) are small non-coding RNA, 20–22 nucleotides
in length, that regulate gene expression at post-transcriptional lev-
els. They act by blocking translation or inducing degradation of the
target mRNA after hybridization to its 30-untranslated region (UTR)
[12]. Actually, >1000 miR have been identified in humans and they
are involved in the regulation of at least one third of all translated
genes. MicroRNA are implied in the regulation of many cell pro-
cesses such as metabolism, differentiation, proliferation [13] and
death [14]. miR-210 is the microRNA most frequently identified
in response to hypoxia and has been identified in a microarray
analysis as the predominant miR induced by hypoxia in pancreatic
cancer cell lines as its induction was dependent on HIF-1a [15].
204 miR-210: A marker of hypoxia in prostate cancerThis induction of miR-210 under hypoxia was confirmed in other
cell lines, such as breast, head and neck, lung, colon, and renal can-
cer cell lines [16]. Recently, miR-210 have been associated with
poor prognosis in early breast cancer in which miR-210 levels
above the median associated with lower survival at 10 years [17].
Additionally, microarray analysis revealed that hypoxia induced
not only miR-210, but also miR-373 in Hela cells (8.4 and 5.6-fold
increase, respectively) [18].
In this study, we hypothesized that miR-210 or miR-373
expression in human prostate cancer cell lines would correlate
with hypoxia and radiosensitivity. To validate miR-210 or
miR-373 as a hypoxic marker, we have examined and correlated
their expression with other well-known tumor hypoxia markers.
Furthermore, to investigate their therapeutic properties, we have
examined cell survival after irradiation in combination with miR
inhibition upon hypoxia.
Materials and methods
Cell culture and hypoxia treatment
The human cancer prostate cell lines LNCaP, DU145, and PC3
were purchased from American Type Culture Collection (ATCC;
Manassas, VA). Cells were grown as monolayer, in RPMI-1640
(LNCaP, PC3) and McCoy-5A medium with glutamine, supple-
mented with 10% fetal calf serum. Cells were plated at a density
of 5  105 per 6 cm dish a day before the start of the experimentFig. 1. Quantitative real-time PCR of HIF-1a (A), CA IX (B) and VEGF (C) mRNA in PC3 (bla
normoxia or anoxia for the indicated time points. All results are normalized to GAPDH
experiments.and transferred to a hypoxic culture chamber (MACS VA500 micro-
aerophilic workstation, Don Whitley Scientific, Shipley, UK). The
atmosphere in the chamber consisted of 0% O2, 5% CO2, 5% H2
and residual N2. Normoxic dishes were incubated in parallel in
air with 5% CO2.MicroRNA qRT-PCR
Total RNA from cultured cells was extracted with TRizol reagent
(Invitrogen, Breda, The Netherlands) as previously described [19].
Total RNA (10 ng) was transcribed using TaqMan microRNA reverse
transcription kit (Applied Biosystems) according to manufacturer’s
instructions. Products were amplified by PCR using TaqMan Univer-
sal PCR Master Mix kit (Applied Biosystems). Primers were pur-
chased from Applied Biosystems: hsa-miR-210 (CUGUGCGUG
UGACAGCGGCUGA), hsa-miR-373 (GAAGUGCUUCGAUUUUGGG-
GUGU). Values for each miR were normalized to expression levels
of microRNA RNU6B (CGCAAGGAUGACACGCAAAUUCGUGAAGC-
GUUCCAUAUUUUU). Real-time PCR was performed in ABI 7500
(Applied Biosystems).mRNA qRT-PCR
Total RNA (1 lg) was transcribed using iScript cDNA synthesis
kit (BioRad Laboratories). cDNA was then amplified using SYBR
Green Master Mix (Applied Biosystems). Values for each gene were
normalized to expression levels of GAPDH RNA. Following primers,ck), LNCaP (gray) and DU145 (white) human prostate cancer cell lines in response to
mRNA expression. Data are represented as the mean ± SD of three independent
L. Quero et al. / Radiotherapy and Oncology 101 (2011) 203–208 205specific for the hypoxia response genes HIF-1a, CAIX and VEGF
were used: HIF-1a (F-ATCGCGGGGACCGATT and R-CGACGTTCA-
GAACTTATCTTTTTCTT), CAIX (F-ATCCTAGCCCTGGTTTTTGG and R-
GCTCACACCCCCTTTGGTT), VEGF (F-GACTCCGGCGGAAGCAT and
R-TCCGGGCTCGGTGATTTA), GAPDH (F-GCACCACCAACTGCTTAGCA
and R-TGGCAGTGATGGCATGGA) and 18S rRNA (F-AGTCCCTGC
CCTTTGTACACA and R-GATCCGAGGGCCTCACTAAAC).Transfection with miR-210 inhibitor
miR-210 inhibitor was purchased from Exiqon company
(Vedbæk, Denmark) and was based on miRCURY LNA™ microRNA
Knockdown technology. Cells were transfected 10 min before hy-
poxia treatment with miR-210 inhibitor (final concentration of
78 nM) using lipofectamine 2000 (Invitrogen, Breda, The Nether-
lands) according to the manufacturer’s recommendations. Control
consisted of scramble miR inhibitor 30-fluorescein labeled (Exiqon,
Vedbæk, Denmark). The sequences of the miR-210 inhibitor
and the scramble miR were 50-TCAGCCGCTGTCACACGCACAG-30 and
50-GTGTAACACGTCTATACGCCCA-30, respectively. Transfection
efficiency was evaluated by fluorescence microscopy (Leica
Microsystems).Cell irradiation
Irradiation was performed using a MCN 225 Philips 225 kV
X-ray irradiator (Philips, Eindhoven, Netherlands), at a dose rateFig. 2. Quantitative real-time PCR of miR-210 expression in PC3 (A), LNCaP (B) and DU1
indicated time points. All results are normalized to microRNA RNU-6B expression. Dataof 0.7 Gy/min. During irradiation, cells were placed on ice into
air-tight sealed chambers to avoid modification of oxygen
concentration.Clonogenic survival assay
Cells were exposed for 10 min to miR210 inhibitor or scramble
miR before exposure to anoxia or normoxia for 24 h. After irradia-
tion, cells were trypsinized and plated in triplicate for clonogenic
survival. Cells were allowed to form colonies during 14 days before
fixation and staining with 0.2% methylene blue in 70% ethanol. Col-
onies containing more than 50 cells were scored. Surviving fraction
was calculated as the ratio between the number of counted colonies
and the number of plated cells, corrected for plating efficiency (PE).Statistics
All statistical analyses were performed with SPSS 12.0.1 for
Windows (SPSS Inc., 2003, Chicago, USA). A p < 0.05 was consid-
ered significant.
Results
First we examined the hypoxia responsiveness of the three dif-
ferent prostate carcinoma cell lines by assessing the HIF-1a, CA IX
and VEGF gene expression upon anoxic exposure relative to the
normoxic control conditions. Anoxia resulted in an increased45 (C) human prostate cancer cell lines in response to normoxia or anoxia for the
are represented as the mean ± SD of two independent experiments.
206 miR-210: A marker of hypoxia in prostate cancerHIF-1a expression reaching a plateau at 48 h exposure for the PC3
and LNCaP cell lines, while no increase was observed for the DU145
(Fig. 1A). In general, the increased HIF-1a expression was higher in
the androgen dependent LNCaP prostate cell line. Corresponding
with the increased HIF-1a expression, the expression of the HIF-
responsive downstream targets CAIX and VEGF was also increased
upon anoxic exposure, again with higher expression levels in the
androgen dependent cell line (Fig. 1B and C). Surprisingly, although
no increased HIF-1a expression was observed in the DU145 cells,
CAIX and VEGF expression levels were increased. GAPDH expres-
sion was not significantly altered upon anoxia, in all three prostate
cancer cell lines, in comparison with the house keeping gene 18S
rRNA expression (data not shown).
Next, we investigated how anoxia influences miR-210 expres-
sion. Growth under normoxic conditions did not seem to influence
miR-210 expression levels (Fig. 2), even not at higher cell densities
(72 h time point), except for the DU145 cells. However, this 72 h
data point should be taken with caution (very large standard devi-
ation). Anoxia exposure resulted in an increased miR-210 expres-
sion for all investigated cell lines, with a preference for the
androgen-independent cell lines DU145 and PC3 (Fig. 2), indicating
that miR-210 is a more stable surrogate chronic hypoxia marker in
prostate cell lines.
miR-210 expression was significantly correlated with CA IX and
VEGF mRNA expressions, in androgen-independent cell lines, with
respectively: p = 0.03 and 0.002 (DU145) and p = 0.001 and 0.02
(PC3). Only miR-210 and VEGF mRNA expression was significantly
correlated in the androgen-dependant cell line LNCaP (p = 0.002).Fig. 3. Quantitative real-time PCR of miR-373 expression in PC3 (A), LNCaP (B) and DU1
indicated time points. All results are normalized to microRNA RNU-6B expression. DataAdditionally, we also investigated miR-373 levels under anoxia.
Anoxia exposure did not seem to influence miR-373 expression in
all cell lines tested (Fig. 3). miR-373 expression levels were extre-
mely low both in normoxic and anoxic conditions (Ct-values range
between 34 and 40).
To examine miR-210 as a potential therapeutic target in pros-
tate cancer cells, we exposed PC3 cells to 78 nM LNA miR-210
inhibitor during 24 h under anoxia. The increased miR-210 expres-
sion of a scrambled inhibitor upon anoxic exposure could be res-
cued with a specific miR-210 inhibitor (Fig. 4A). The difference in
miR-210 expression after miR-210 specific inhibitor treatment
was statistically significant compared with the scramble control
inhibitor (p = 0.03). We observed a dose–response relationship be-
tween miR-210 inhibitor concentration during anoxia and inhibi-
tion of miR-210 expression in PC3 cell line. Furthermore, miR-
210 inhibition decreased the anoxia tolerance to approximately
72% (Fig. 4B), indicating an unexpected statistically significant
mortality upon miR-210 inhibition (p = 0.01).
Based on these results, we investigated if this decreased anoxia
tolerance could lead to an increased sensitization of prostate cells
to irradiation. PC3 cells were exposed to miR-210 inhibition during
24 h under anoxia and cells were afterward exposed to a range of
irradiation doses. Cells incubated with a scrambled control inhibi-
tor showed a significant resistance phenotype when exposed to
anoxia, the oxygen enhancement ratio (OER) was calculated to be
2.0 ± 0.3 (mean ± SD). Incubation of cells to a specific miR-210
inhibitor under normoxic conditions had no influence on radiosen-
sitivity (Fig. 5). Similar data were found upon incubation under45 (C) human prostate cancer cell lines in response to normoxia or anoxia for the
are represented as the mean ± SD of two independent experiments.
Fig. 4. (A) Quantitative real-time PCR of miR-210 expression in PC3 cells after addition of 78 nM specific miR-210 (A) or scrambled (S) inhibitor during 24 h normoxia (N) or
anoxia (A). Data are normalized to microRNA RNU-6B expression. (B) Clonogenic survival of PC3 cells exposed to 78 nM specific miR-210 (AA) or scrambled (AS) inhibitor
during 24 h anoxia. Data are represented as the mean ± SD of three independent experiments.
Fig. 5. Clonogenic survival of PC3 cells after irradiation under normoxic (black) and
anoxic (white) conditions. Cells were pre-incubated under the respective conditions
with 78 nM specific miR-210 (squares) or scrambled (circles) inhibitor. Data are
represented as the mean ± SD of three independent experiments. Oxygen enhance-
ment ratio (OER) values for scramble miR and miR-210 inhibitor.
L. Quero et al. / Radiotherapy and Oncology 101 (2011) 203–208 207anoxic conditions, indicating that miR-210 inhibition could not re-
sult in a radiosensitization upon anoxia.
Discussion
Hypoxic tumors are associated with poor prognosis and resis-
tance to radiotherapy [3–5,20–22]. For prostate cancer, tumor
hypoxia is associated with tumor aggressiveness, high histological
grade and advanced clinical stage [6,23,24]. Increased hypoxia
marker expression is associated with poor disease control after
radiotherapy. Elevated HIF-1a and VEGF expressions on tumor
biopsies from patients treated for prostate cancer by radiotherapy
have been associated with poor biochemical control of the disease
[25]. In our study, all three investigated cell lines proved to be
hypoxia-responsive as evidenced by increased HIF-1a, CAIX and
VEGF mRNA expression. Although we did not observed any
HIF-1a mRNA induction in DU145 after anoxia, CAIX and VEGF
expression levels were increased which could be explained by
post-translational regulation of HIF-1a [26].
miR-210 is the microRNA most frequently associated with
tumor hypoxia [16,17,27] and increased miR-210 expression was
observed in vitro after 24 h exposure to hypoxia in pancreatic,
breast, head and neck, lung, colon, and renal cancer cell lines
[15]. So far, it was not known if miR-210 follows the same pattern
in prostate cancer cell lines exposed to low oxygen concentrations.In our study, we observed miR-210 expression consistently
increased upon anoxia exposure in prostate cancer cell lines irre-
spective of the androgen dependency. Furthermore, miR-210 up-
regulation was more consistently associated with chronic hypoxia
across prostate cancer cell lines compared to CA IX, VEGF and HIF-
1a. This was somewhat anticipated since several studies have
shown that miR-210 was a target of HIF-1a [16,17,27]. A functional
hypoxia-responsive element (HRE) on the genomic DNA, upstream
of the miR-210 coding gene, confirming miR-210 was regulated by
HIF-1a [15]. Our results are furthermore in accordance with the
observed association between HIF-1a, GLUT-1 expression and
miR-210 expression in primary tumor samples from patients with
head and neck cancer [15]. These data suggest that miR-210
expression might be a valuable surrogate marker for chronic hy-
poxia, a type of hypoxia potentially easier to tackle with radiation
in contrast with acute hypoxia. Additionally, recent studies con-
cluded that analysis of circulating miR-210 could be used as a can-
cer biomarker in large B-cell non Hodgkin lymphoma [28] and
pancreatic cancer [29]. Circulating miR210 analysis is a promising
technique because it is a non-invasive method permitting repeated
measurements over time.
Although it has been demonstrated that miR-210 and miR-373
was up-regulated upon hypoxia exposure in cervical and breast can-
cer cell lines [18], we only observed an increased miR-210 expres-
sion upon anoxia, while no significant miR-373 expression in the
prostate cancer cell lines. miR-373 expression levels were generally
low and Ct values ranged from 34 to 40. In the previous report, we
could not find any information about Ct values, but our results seem
to be in accordance with Schaefer et al., who could not detect any
miR-373 expression in RT-qPCR in prostate cancer tissues (Ct values
>35) [30]. These findings indicate that only miR-210 and not miR-
373 could be used a marker for chronic hypoxia.
Several miR-210 targets have been identified such as HOXA1
(effect on cell proliferation and cell oncogenic transformation),
FGFRL1 (effect on cell proliferation), HOXA9 (effect on cell prolifer-
ation and apoptotic cell death) [15] and RAD52 (effect on DNA
repair through homologous recombination) [18]. Based on the
functions of these targets, we hypothesized that miR-210 might
be a potential therapeutic target. miR-210 inhibition was effective
under anoxia and resulted in a decreased clonogenic survival rela-
tive to a control inhibitor. These results prompted us to investigate
whether miR-210 inhibition would enhance the effect of radiother-
apy. As expected, a radioresistant phenotype was observed in our
prostate cancer cell line model after anoxia exposure relative to
normoxia.
208 miR-210: A marker of hypoxia in prostate cancerOxygen enhancement ratio (OER) was lower than expected: 2
for PC3 cell line in this study vs 3 for most cells. Reduced OER un-
der chronic hypoxia (>24 h) was also observed in PC3 by Stewart et
al. [31] and was most common in p53 mutant cell lines such as PC3
cell line [32,33].
However, pretreatment with miR-210 inhibitors did not sensi-
tize cells to irradiation, neither under normoxia nor upon anoxia,
indicating that miR-210 is not a therapeutic target. Possibly, down-
stream miR-210 targets such as RAD52 are more suited to inhibit,
which is involved in homologous recombination and has a direct
effect on radiation efficacy.
Conclusion
miR-210 might be an interesting marker of chronic hypoxia
irrespective of the androgen dependency and should, therefore,
be tested as a prognostic marker in high risk prostate cancer pa-
tients. Our results need to be confirmed in vivo on primary tumor
sections with comparison to HIF-1a, CA IX and VEGF expressions.
Analysis of circulating miR-210 could be an alternative to primary
tumor staining and could be tested in patients with prostate cancer
as a biomarker. Although inhibition of miR-210 on its own results
in a higher cell death upon anoxia, no extra-therapeutic gain was
obtained for concomitant association with radiotherapy.
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